Get more information on Drug Discovery Informatics Market - Request Sample Report
The Drug Discovery Informatics Market size was valued at USD 3.14 billion in 2023 and is expected to reach USD 8.12 billion by 2032 and grow at a CAGR of 11.16% over the forecast period 2024-2032.
The global drug discovery informatics market is experiencing robust growth because of development in high-performance computing and an increasing number of demands for innovative molecules of drugs. Other factors of this growth include an expanded volume of drug discovery data and more intense market competition. For instance, in 2021 the company, Certara, Inc., brought out the latest version of the PBPK Simulator - Simcyp Physiologically-based Pharmacokinetic (Simcyp PBPK), designed with newly added models on pregnant and lactating women drug interactions. These innovations will thus optimize how drug safety and efficacy may be enhanced toward a heightened impact on informatics.
In integration solutions such as Curve Therapeutics Ltd. selecting the CDD Vault to manage its data, timelines for discovering drugs are greatly streamlined in an environment where data sharing collaboratively between pharma, biotech, and academic groups is securely conducted. This is important because it emphasizes the market amid the existing impacts of COVID-19 that have pushed the demand for in silico tools and virtual screening methodologies to search for efficacious treatment. Companies have also been developing platforms that are tailored to COVID-19 research, for instance, IBM created the visual molecular explorer platform that aids in the study of molecules that target the SARS-CoV-2 virus.
It involves a driving force in precision medicine that allows for individually designed treatments based on their respective genetic or molecular profiling. Data solutions capable of managing vast databases, processing, and analytical methods have increased exponentially and in large numbers, contributing toward expansion in data as well as drug development costs are significant in this regard while using data analytics to increase minimization of errors helps to reduce timelines further in boosting the market.
The other driving forces in this market include a global increase in research expenditure for informatics by pharmaceutical and biotechnology companies, with rising interest in rare disease and orphan drug research. For this reason, the market offers a comprehensive range of tools to enable data gathering, processing, and visualization. Regional companies have been emphasizing joint research initiatives; however, growing needs to speed up the development of new medications and higher costs of IT infrastructure for healthcare also play a crucial role in fueling this market. Overall, the drug discovery informatics development process is transforming drug development efficiency, and growth in this market will further accelerate within the next few years.
Drivers
The drug discovery informatics market is significantly driven by the growing interest in discovering drugs through informatics software and the improvements that are being made in high-performance computing and web services. The demand for in-silico modeling tools is increasing along with the increase in demand for new drug molecules, but the very high price for informatics software sometimes restrains this growth significantly. Simultaneously, growth in the expanding biotechnology and biologics sectors, particularly in emerging markets, provides vast business opportunities.
The market increases as advanced IT applications drive the competition between entities in the drug discovery market. For instance, in 2021, Certara, Inc. released version 20 of its Simcyp Physiologically-based Pharmacokinetic (PBPK) Simulator. It has models quantifying drug actions during pregnancy and lactation—critical decisions on optimizing medicines' safety and efficacy.
The adoption of informatics solutions by companies is also becoming a trend to hasten and streamline the process of drug discovery. Curve Therapeutics Ltd. is using CDD Vault for the secure management of data related to its genetically encoded Microcycle platform that promotes real-time data sharing and collaboration between the pharmaceutical, biotech, and academia sectors.
In addition, the continuous efforts in COVID-19 drug discovery have also expanded the market size. Scientists are using in silico tools and virtual screening to identify drug candidates that target viral proteins and ACE2 receptors. Platforms like IBM's Visual Molecular Explorer facilitate research by providing AI-generated models to optimize potential COVID-19 treatments, further strengthening the market.
Restraints
High Costs of Informatics Software
Complexity and Integration Challenges
By Workflow
The workflow segment accounted for approximately 40.0% share of Discovery Informatics, the largest share in that category. This is primarily because this segment is essential to early-stage drug research where high-throughput screening, genomics, and bioinformatics are used to increase the speed of potential candidates being identified. Increasingly, the volume of genomic and proteomic data with more sophisticated tools in analyzing such data has created more demand for discovery informatics. Moreover, the growing interest in precision medicine and the necessity of streamlining R&D processes has further strengthened this segment in the market.
Biocontent Management is likely to emerge as the fastest-growing workflow segment. This is due to the need for strong data storage and retrieval systems to manage and integrate large datasets, including gene sequences, protein structures, and clinical trial information. It is crucial for the pharmaceutical industry and research institutions that are increasingly focusing on implementing collaborative and data-accessible biocontent management solutions for modern drug discovery workflows. The compound annual growth rate (CAGR) for this segment is approximately 12.0%.
By Services
Sequence analysis platform dominated the services category with a share of nearly 35.0% in 2023. Because of the critical functions in genomics and next-generation sequencing analysis from which researchers could find genetic markers and possible drug targets. Growth in precision medicine also has been based on sequence analysis platforms for personalized treatment, thus solidifying dominance for this segment. Since they improve the precision and speed of genetic data analysis, these technologies have become a part of drug discovery and have gained adoption recently.
The services category is the fastest-growing segment by molecular modeling, which is estimated to grow at around 15.0% CAGR over the forecast period. The growth in this area is due to the growing applications in drug design and structural biology, as molecular modeling software simulates the molecular level of interactions of a drug. The growth is due to more and more companies using computational chemistry and machine learning tools. These tools have improved the predictability of molecular modeling at the molecular level regarding the efficacy of drugs and the reduction of time-to-market. With the focus placed on developing innovative drug molecules, molecular modeling services have gained a lot of demand.
North America held the highest share in the market revenue account, with 39.09% in 2023, because of the efforts being put into research and development concerning drug discovery. Advances in data mining, as well as analytics tools, do support drug discovery and drug development processes in North America, leading to a significant increase in their revenue market share account to contribute significantly to that overall revenue. Advanced informatics tools and techniques help extract valuable insights from the information, thereby helping researchers and pharmaceutical companies in deciding to speed up drug discovery and development. In addition, global efforts to expedite COVID-19 drug discovery have added momentum to the market in this region. Several companies have come up with specific web services and solutions developed for each stage of COVID-19 drug development. As a result, in June 2020, the molecule-targeting SARS-CoV-2 analysis of IBM's Visual Molecular Explorer involved open-source AI-generated artifacts for conducting early-stage optimization on the potential treatments. Besides, the North American companies have been recently very actively involved in joint ventures and collaborative research, which further drives the market growth. In December 2020, A2i Therapeutics announced that it would enter a joint venture with Atomwise, a leading AI-driven small-molecule drug discovery company, as well as with FutuRx, further increasing its portfolio of collaborative research. These research fields are spread over oncology, immunology, infectious disease, neuroscience, as well as clotting disorders. This requires significant growth in drug discovery informatics and propels the overall market.
On the other hand, the Asia-Pacific region is expected to grow with the highest CAGR at 11.9% during the forecast period. Pharmaceutical and biopharmaceutical industries are being expanded at a rapid growth rate while a growing number of contract research organizations also support such growth. China and India, among others, have been more in the limelight in their growth possibilities because of a significantly more developed infrastructure in drug development and discovery that is promoted through a good pipeline of skilled professionals and cost structures.
Need any customization research on Drug Discovery Informatics Market - Enquiry Now
Schrödinger (Maestro)
PerkinElmer (Signals Notebook and ChemOffice)
BIOVIA (Dassault Systèmes) (BIOVIA Discovery Studio)
Benchling (Benchling Platform)
Genedata (Genedata Screener)
Thermo Fisher Scientific (Thermo Scientific Compound Discoverer)
Dotmatics (Dotmatics Platform)
Aragen Life Sciences (Drug Discovery Informatics Solutions)
GVK Biosciences (GVK BIO) (GVK BIO Informatics Solutions)
Molecular Discovery Ltd. (MoKa)
Lhasa Limited (Derek Nexus)
In February 2023, Insilico Medicine, a clinical-stage company specializing in generative AI-driven drug discovery, announced it had received FDA Orphan Drug Designation for its AI-discovered and AI-designed treatment for Idiopathic Pulmonary Fibrosis.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | US$ 3.14 billion |
| Market Size by 2032 | US$ 8.12 billion |
| CAGR | CAGR of 11.16% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Workflow (Discovery Informatics, Biocontent Management) • By Services (Sequence Analysis Platform, Molecular Modelling, Docking, Clinical Trial Data Management, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Schrödinger, PerkinElmer, BIOVIA, Benchling, Genedata, Thermo Fisher Scientific, Dotmatics, Aragen Life Sciences, GVK Biosciences, Molecular Discovery Ltd., Lhasa Limited. |
| Key Drivers | • Advancements in High-Performance Computing, In-Silico Modeling, and Industry Collaboration Fuel Growth in the Drug Discovery Informatics Market |
| Restraints | • High Costs of Informatics Software • Complexity and Integration Challenges |
Ans: The Drug Discovery Informatics market size was valued at US$ 3.14 billion in 2023.
Ans: The Drug Discovery Informatics Market is to grow at a CAGR of 11.16% over the forecast period 2024-2032.
Outsourced, and In-house are the sub segments of component of Drug Discovery Informatics market.
Drivers, Restraints, Opportunities, and Challenges are the factors of marketing dynamics Drug Discovery Informatics market.
The growing interest in, funding for, and demand for research into orphan drugs and uncommon diseases utilize informatics to concentrate on drug discovery are the key drivers of the Drug Discovery Informatics market.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends, (2023), by Region
5.3 Drug Volume: Production and usage volumes of pharmaceuticals.
5.4 Healthcare Spending: Expenditure data by government, insurers, and out-of-pocket by patients.
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Service Benchmarking
6.3.1 Service specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Service launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Drug Discovery Informatics Market Segmentation, by Workflow
7.2 Discovery Informatics
7.2.1 Discovery Informatics Market Trends Analysis (2020-2032)
7.2.2 Discovery Informatics Market Size Estimates and Forecasts to 2032 (USD Million)
7.3 Biocontent Management
7.3.1 Bio content Management Market Trends Analysis (2020-2032)
7.3.2 Bio content Management Market Size Estimates and Forecasts to 2032 (USD Million)
8. Drug Discovery Informatics Market Segmentation, by Services
8.2 Sequence Analysis Platform
8.2.1 Sequence Analysis Platform Market Trends Analysis (2020-2032)
8.2.2 Sequence Analysis Platform Market Size Estimates and Forecasts to 2032 (USD Million)
8.3 Molecular Modelling
8.3.1 Molecular Modelling Market Trends Analysis (2020-2032)
8.3.2 Molecular Modelling Market Size Estimates and Forecasts to 2032 (USD Million)
8.4 Docking
8.4.1 Docking Market Trends Analysis (2020-2032)
8.4.2 Docking Market Size Estimates and Forecasts to 2032 (USD Million)
8.5 Clinical Trial Data Management
8.5.1 Clinical Trial Data Management Market Trends Analysis (2020-2032)
8.5.2 Clinical Trial Data Management Market Size Estimates and Forecasts to 2032 (USD Million)
8.6 Others
8.6.1 Others Market Trends Analysis (2020-2032)
8.6.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Drug Discovery Informatics Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
9.2.3 North America Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.2.4 North America Drug Discovery Informatics Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
9.2.5 USA
9.2.5.1 USA Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.2.5.2 USA Drug Discovery Informatics Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
9.2.6 Canada
9.2.6.1 Canada Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.2.6.2 Canada Drug Discovery Informatics Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
9.2.7 Mexico
9.2.7.1 Mexico Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.2.7.2 Mexico Drug Discovery Informatics Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
9.3 Europe
9.3.1 Eastern Europe
9.3.1.1 Trends Analysis
9.3.1.2 Eastern Europe Drug Discovery Informatics Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
9.3.1.3 Eastern Europe Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.3.1.4 Eastern Europe Drug Discovery Informatics Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
9.3.1.5 Poland
9.3.1.5.1 Poland Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.3.1.5.2 Poland Drug Discovery Informatics Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
9.3.1.6 Romania
9.3.1.6.1 Romania Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.3.1.6.2 Romania Drug Discovery Informatics Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
9.3.1.7 Hungary
9.3.1.7.1 Hungary Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.3.1.7.2 Hungary Drug Discovery Informatics Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
9.3.1.8 Turkey
9.3.1.8.1 Turkey Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.3.1.8.2 Turkey Drug Discovery Informatics Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
9.3.1.9 Rest of Eastern Europe
9.3.1.9.1 Rest of Eastern Europe Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.3.1.9.2 Rest of Eastern Europe Drug Discovery Informatics Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
9.3.2 Western Europe
9.3.2.1 Trends Analysis
9.3.2.2 Western Europe Drug Discovery Informatics Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
9.3.2.3 Western Europe Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.3.2.4 Western Europe Drug Discovery Informatics Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
9.3.2.5 Germany
9.3.2.5.1 Germany Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.3.2.5.2 Germany Drug Discovery Informatics Market Estimates and Forecasts, by Services(2020-2032) (USD Million)
9.3.2.6 France
9.3.2.6.1 France Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.3.2.6.2 France Drug Discovery Informatics Market Estimates and Forecasts, by Services(2020-2032) (USD Million)
9.3.2.7 UK
9.3.2.7.1 UK Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.3.2.7.2 UK Drug Discovery Informatics Market Estimates and Forecasts, by Services(2020-2032) (USD Million)
9.3.2.8 Italy
9.3.2.8.1 Italy Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.3.2.8.2 Italy Drug Discovery Informatics Market Estimates and Forecasts, by Services(2020-2032) (USD Million)
9.3.2.9 Spain
9.3.2.9.1 Spain Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.3.2.9.2 Spain Drug Discovery Informatics Market Estimates and Forecasts, by Services(2020-2032) (USD Million)
9.3.2.10 Netherlands
9.3.2.10.1 Netherlands Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.3.2.10.2 Netherlands Drug Discovery Informatics Market Estimates and Forecasts, by Services(2020-2032) (USD Million)
9.3.2.11 Switzerland
9.3.2.11.1 Switzerland Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.3.2.11.2 Switzerland Drug Discovery Informatics Market Estimates and Forecasts, by Services(2020-2032) (USD Million)
9.3.2.12 Austria
9.3.2.12.1 Austria Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.3.2.12.2 Austria Drug Discovery Informatics Market Estimates and Forecasts, by Services(2020-2032) (USD Million)
9.3.2.13 Rest of Western Europe
9.3.2.13.1 Rest of Western Europe Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.3.2.13.2 Rest of Western Europe Drug Discovery Informatics Market Estimates and Forecasts, by Services(2020-2032) (USD Million)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Drug Discovery Informatics Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
9.4.3 Asia Pacific Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.4.4 Asia Pacific Drug Discovery Informatics Market Estimates and Forecasts, by Services(2020-2032) (USD Million)
9.4.5 China
9.4.5.1 China Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.4.5.2 China Drug Discovery Informatics Market Estimates and Forecasts, by Services(2020-2032) (USD Million)
9.4.6 India
9.4.5.1 India Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.4.5.2 India Drug Discovery Informatics Market Estimates and Forecasts, by Services(2020-2032) (USD Million)
9.4.5 Japan
9.4.5.1 Japan Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.4.5.2 Japan Drug Discovery Informatics Market Estimates and Forecasts, by Services(2020-2032) (USD Million)
9.4.6 South Korea
9.4.6.1 South Korea Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.4.6.2 South Korea Drug Discovery Informatics Market Estimates and Forecasts, by Services(2020-2032) (USD Million)
9.4.7 Vietnam
9.4.7.1 Vietnam Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.2.7.2 Vietnam Drug Discovery Informatics Market Estimates and Forecasts, by Services(2020-2032) (USD Million)
9.4.8 Singapore
9.4.8.1 Singapore Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.4.8.2 Singapore Drug Discovery Informatics Market Estimates and Forecasts, by Services(2020-2032) (USD Million)
9.4.9 Australia
9.4.9.1 Australia Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.4.9.2 Australia Drug Discovery Informatics Market Estimates and Forecasts, by Services(2020-2032) (USD Million)
9.4.10 Rest of Asia Pacific
9.4.10.1 Rest of Asia Pacific Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.4.10.2 Rest of Asia Pacific Drug Discovery Informatics Market Estimates and Forecasts, by Services(2020-2032) (USD Million)
9.5 Middle East and Africa
9.5.1 Middle East
9.5.1.1 Trends Analysis
9.5.1.2 Middle East Drug Discovery Informatics Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
9.5.1.3 Middle East Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.5.1.4 Middle East Drug Discovery Informatics Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
9.5.1.5 UAE
9.5.1.5.1 UAE Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.5.1.5.2 UAE Drug Discovery Informatics Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
9.5.1.6 Egypt
9.5.1.6.1 Egypt Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.5.1.6.2 Egypt Drug Discovery Informatics Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
9.5.1.7 Saudi Arabia
9.5.1.7.1 Saudi Arabia Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.5.1.7.2 Saudi Arabia Drug Discovery Informatics Market Estimates and Forecasts, by Services(2020-2032) (USD Million)
9.5.1.8 Qatar
9.5.1.8.1 Qatar Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.5.1.8.2 Qatar Drug Discovery Informatics Market Estimates and Forecasts, by Services(2020-2032) (USD Million)
9.5.1.9 Rest of Middle East
9.5.1.9.1 Rest of Middle East Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.5.1.9.2 Rest of Middle East Drug Discovery Informatics Market Estimates and Forecasts, by Services(2020-2032) (USD Million)
9.5.2 Africa
9.5.2.1 Trends Analysis
9.5.2.2 Africa Drug Discovery Informatics Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
9.5.2.3 Africa Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.5.2.4 Africa Drug Discovery Informatics Market Estimates and Forecasts, by Services(2020-2032) (USD Million)
9.5.2.5 South Africa
9.5.2.5.1 South Africa Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.5.2.5.2 South Africa Drug Discovery Informatics Market Estimates and Forecasts, by Services(2020-2032) (USD Million)
9.5.2.6 Nigeria
9.5.2.6.1 Nigeria Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.5.2.6.2 Nigeria Drug Discovery Informatics Market Estimates and Forecasts, by Services(2020-2032) (USD Million)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Drug Discovery Informatics Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
9.6.3 Latin America Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.6.4 Latin America Drug Discovery Informatics Market Estimates and Forecasts, by Services(2020-2032) (USD Million)
9.6.5 Brazil
9.6.5.1 Brazil Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.6.5.2 Brazil Drug Discovery Informatics Market Estimates and Forecasts, by Services(2020-2032) (USD Million)
9.6.6 Argentina
9.6.6.1 Argentina Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.6.6.2 Argentina Drug Discovery Informatics Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
9.6.7 Colombia
9.6.7.1 Colombia Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.6.7.2 Colombia Drug Discovery Informatics Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
9.6.8 Rest of Latin America
9.6.8.1 Rest of Latin America Drug Discovery Informatics Market Estimates and Forecasts, by Workflow (2020-2032) (USD Million)
9.6.8.2 Rest of Latin America Drug Discovery Informatics Market Estimates and Forecasts, by Services (2020-2032) (USD Million)
10. Company Profiles
10.1 Schrödinger
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Products/ Services Offered
110.1.4 SWOT Analysis
10.2 PerkinElmer
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Products/ Services Offered
10.2.4 SWOT Analysis
10.3 BIOVIA (Dassault Systèmes)
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Products/ Services Offered
10.3.4 SWOT Analysis
10.4 Benchling
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Products/Services Offered
10.4.4 SWOT Analysis
10.5 Genedata
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Products/Services Offered
10.5.4 SWOT Analysis
10.6 Thermo Fisher Scientific
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Products/Services Offered
10.6.4 SWOT Analysis
10.7 Dotmatics
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Products/Services Offered
10.7.4 SWOT Analysis
10.8 Aragen Life Sciences
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Products/Services Offered
10.8.4 SWOT Analysis
10.9 GVK Biosciences (GVK BIO)
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/Services Offered
10.9.4 SWOT Analysis
10.10 Molecular Discovery Ltd.
10.10.1 Company Overview
10.10.2 Financial
10.10.3 Products/Services Offered
10.10.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By Workflow
Discovery Informatics
Biocontent Management
By Services
Sequence Analysis Platform
Molecular Modelling
Docking
Clinical Trial Data Management
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of the product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The Healthcare Supply Chain Management Market will reach USD 10.14 Bn by 2031, and was valued at USD 3 Bn in 2023, and grow at a CAGR of 14.5 % by 2024-2031.
The Pharmacovigilance and Drug Safety Software Market Size was valued at USD 6.83 billion in 2022, and is expected to reach USD 14.86 billion by 2030, and grow at a CAGR of 10.2% over the forecast period 2023-2030.
The Artificial Cervical Disc Market Size was valued at USD 1.75 billion in 2023 and is expected to reach USD 2.23 billion by 2031 and grow at a CAGR of 3.1% over the forecast period 2024-2031.
The Smart Inhalers Market size amounted to USD 15.77 Billion In 2023 & is estimated to reach USD 78.36 Billion by 2032 and increase at a compound annual growth rate of 19.5% between 2024 and 2032.
The Pharmaceutical Excipients Market Size was valued at USD 9.09 billion in 2023 and is expected to reach USD 14.52 billion by 2031, and grow at a CAGR of 6.02% over the forecast period 2024-2031.
The Corporate Wellness Market Size was valued at USD 64.11 billion in 2023 and will reach USD 123.35 billion in 2032, with a CAGR of 7.60% by 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
